|
BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations. |
| |
|
No Relationships to Disclose |
| |
|
|
Travel, Accommodations, Expenses - Merck |
| |
|
|
Stock and Other Ownership Interests - Merck |
Travel, Accommodations, Expenses - Merck |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Takeda |
Speakers' Bureau - Abbvie; Roche; Takeda |
Travel, Accommodations, Expenses - Roche |